PeproMene’s platform and products targeting BAFF-R which is an innovative tumor antigen for treating a broad range of B cell malignancies and autoimmune diseases. BAFF-R targeting immune therapies have great potential to overcome the tumor relapse caused by antigen loss brings hope to those patients with such unmet medical needs. We value investors who share the same passion and welcome you to contact us for further information.

PeproMene Bio, Inc. is a privately held company. Our stock has not been registered under the Securities Act of 1933 (“Securities Act”) or the securities act of any state or any other jurisdiction. Any offering or sale of our stock will be made only to accredited investors pursuant to an exemption from registration under the Securities Act. This website and any press releases, articles and other documents referenced herein contain forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions.
These forward-looking statements include, but are not limited to, statements regarding our drug programs, including their clinical development, such as the timing of clinical trials and expected announcement of data, therapeutic potential and clinical results, and our financial position. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of such statements. We undertake no obligation to update or revise the information contained or referenced herein, whether as a result of new information, future events or circumstances or otherwise.

Press release and Events